Mantle cell lymphoma other imaging findings

Jump to navigation Jump to search

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma other imaging findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma other imaging findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma other imaging findings

on Mantle cell lymphoma other imaging findings

Mantle cell lymphoma other imaging findings in the news

Blogs on Mantle cell lymphoma other imaging findings

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma other imaging findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2] Ali Akram, M.B.B.S.[3]

Overview

PET scan (positron emission tomography) integrated with CT scan may be helpful in the staging and treatment response assessment of mantle cell lymphoma.

Other Imaging Studies

There seems to no concrete consensus about the usefulness of PET/CT scan in lymphomas. However, in some studies it has been shown that it may be helpful in the staging and treatment response assessment of mantle cell lymphoma, which is considered a fluorodeoxyglucose (FDG)-avid tumor and shows activity on the PET scan.[1]


References

  1. Saar Gill, Max Wolf, H. Miles Prince, Henry Januszewicz, David Ritchie, Rodney J. Hicks & John F. Seymour (2008). "[18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma". Clinical lymphoma & myeloma. 8 (3): 159–165. doi:10.3816/CLM.2008.n.019. PMID 18650179. Unknown parameter |month= ignored (help)

Template:Hematology

Template:WH Template:WS